UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

02 Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Read More Share:

Apr

20 UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Read More Share:

Apr

17 UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More Share:

Apr

13 UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Read More Share:

Mar

18 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Read More Share:

Jan

20 Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Read More Share:

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More Share:

Jan

17 5 U.S. Organizations Receive Support from UCB Community Health Fund

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Categories

Archives

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Notice about cookies

Categories

Archives

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact